RecruitingNot ApplicableNCT05564936

The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis: a Validation Study


Sponsor

Ad scientiam

Enrollment

144 participants

Start Date

Jan 24, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG. ME\&MG contains digital active tests for the assessment of ptosis, breathing, dysarthria, upper- and lower-limb (arms and legs) weakness, treatment follow-up, and validated e-questionnaires related to daily activities, pain, fatigue, sleep, and depression disorders. The objectives of this study are to validate the accuracy, reliability and reproducibility of the unsupervised at-home self-assessment of symptoms on the patient's smartphone with ME\&MG versus the standard in-clinic testing, as well as to evaluate the safety of the solution, its usability and satisfaction.


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Aged over 18 Years
  • Diagnosed with gMG at screening with generalized muscle weakness meeting the clinical criteria for diagnosis of MG, as defined by the MGFA Clinical Classification Class II, III, or IV, and likely not in need of a respirator for the duration of the study, as judged by the investigator
  • With positive serologic testing for anti-AChR autoantibody at screening
  • Have read the information sheet and signed the informed consent form
  • Own a personal smartphone which software version is above 13 for IOS and 8 for Android included
  • Able to use a smartphone
  • Able to read language in which the mobile application is available (French, English, Spanish) and able to understand pictograms

Exclusion Criteria8

  • Subjects having undergone thymectomy Plasma Exchange Therapy or Intravenous Immunoglobulin Therapy within four weeks of screening
  • Subjects having initiated FcRn inhibitor therapy within the four weeks preceding screening
  • Known medical or psychological condition(s) or risk factor(s) that, as judged by the investigator, might interfere with the subject's full participation in the study, pose any additional risk for the subject, or confound the assessment of the subject or outcome of the study.
  • Pregnant and nursing women
  • Person under guardianship or curatorship
  • Current drugs or/and alcohol abuse that could influence performance on the tests, as judged by the investigator
  • Participant included in another ME\&MG clinical study
  • Participant has participated in another clinical study within the previous 30 days of screening or is currently participating in another study that, in the opinion of the Investigator, might interfere with the subject's full participation in the study or confound the assessment of the subject or outcome of the study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEME&MG mobile application

ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG.


Locations(19)

University of Colorado Denver

Aurora, Colorado, United States

University of Florida Health

Jacksonville, Florida, United States

HealthParterns Institute

Bloomington, Indiana, United States

Indiana University Health

Indianapolis, Indiana, United States

University of Kentucky

Lexington, Kentucky, United States

Neurological Associates of Long Island, P.C.

Lake Success, New York, United States

Duke University

Durham, North Carolina, United States

OHSU

Portland, Oregon, United States

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

The University of Tennessee Medical Center

Knoxville, Tennessee, United States

Vanderbilt Health

Nashville, Tennessee, United States

Hôpital Raymond Poincaré

Garches, France

CHU Grenoble

Grenoble, France

Hôpital Salengro

Lille, France

CHRU Nancy

Nancy, France

CHU Nantes

Nantes, France

Pitié-Salpêtrière

Paris, France

CHU de Strasbourg - Hôpital de Hautepierre

Strasbourg, France

CHU Toulouse

Toulouse, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05564936


Related Trials